Transcripta Bio, a company focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel, announced its launch with $10 million ...
Investor Base expands as Transcripta Bio Advances Four-Program Pipeline Toward Multiple Clinical Milestones Transcripta Bio, an AI-powered drug discovery company focused on neurological and ...
PALO ALTO, Calif., May 30, 2025 /PRNewswire/ -- Transcripta Bio today announced a research collaboration with Microsoft Research to accelerate the discovery of disease-gene associations using advanced ...
SOLVE FSHD Announces Strategic Collaboration with Transcripta Bio to Advance Drug Discovery for FSHD
VANCOUVER, British Columbia — SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic ...
Follow this author to personalize your feed and get instant alerts. WHY FOLLOW? Custom Feed: See the stories that matter most to you. Smart Alerts: Get notified about major news as it happens. Update ...
PALO ALTO, Calif., July 22, 2026--(BUSINESS WIRE)--Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, today announced it has raised $24 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results